Yatharth Hospital & Trauma Care Services DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.78×0.76×0.76×0.73×0.75×
1.08×1.09×1.05×1.04×0.92×
15.7%16.9%18.5%22.5%24.9%
0.60×0.60×0.64×0.89×0.76×
1.26×1.26×1.06×1.17×2.66×
9.9%10.7%10.0%17.7%34.9%
10.0%10.0%10.5%21.7%35.1%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

YATHARTH₹923.30

Yatharth Hospital & Trauma Care Services Ltd.

· Pharma & Health
₹ CrorePeersMAXHEALTHMEDANTAFORTISVIYASHTHYROCARESUPRIYASTARSPARCMcap ₹8,896 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.750.730.760.760.78
Interest Burden (Pretax/EBIT) ×0.921.041.051.091.08
EBIT Margin %24.9422.4718.5216.9215.68
Asset Turnover ×0.760.890.640.600.60
Financial Leverage (Assets/Equity) ×2.661.171.061.261.26
ROE (5-step product, year-end total equity) %34.8717.7110.0310.699.91
ROE (owners' profit / average owners' equity) %35.0721.6510.539.989.98
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.